BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9679720)

  • 1. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents.
    Gottdiener JS; Reda DJ; Williams DW; Materson BJ; Cushman W; Anderson RJ
    Circulation; 1998 Jul; 98(2):140-8. PubMed ID: 9679720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Gottdiener JS; Reda DJ; Massie BM; Materson BJ; Williams DW; Anderson RJ
    Circulation; 1997 Apr; 95(8):2007-14. PubMed ID: 9133508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group.
    Papademetriou V; Gottdiener JS; Narayan P; Cushman WG; Zachariah PK; Gottdiener PS; Chase GA
    J Am Coll Cardiol; 1997 Dec; 30(7):1802-8. PubMed ID: 9385910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial.
    Cushman WC; Materson BJ; Williams DW; Reda DJ
    Hypertension; 2001 Oct; 38(4):953-7. PubMed ID: 11641316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
    Wachtell K; Bella JN; Rokkedal J; Palmieri V; Papademetriou V; Dahlöf B; Aalto T; Gerdts E; Devereux RB
    Circulation; 2002 Mar; 105(9):1071-6. PubMed ID: 11877357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Materson BJ; Reda DJ; Cushman WC; Massie BM; Freis ED; Kochar MS; Hamburger RJ; Fye C; Lakshman R; Gottdiener J
    N Engl J Med; 1993 Apr; 328(13):914-21. PubMed ID: 8446138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
    Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
    Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Preston RA; Materson BJ; Reda DJ; Williams DW; Hamburger RJ; Cushman WC; Anderson RJ
    JAMA; 1998 Oct; 280(13):1168-72. PubMed ID: 9777817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular end-diastolic dimensions measured at the P wave and Q wave during a randomized, double-blind one-year follow-up study comparing the effect of atenolol vs. hydrochlorothiazide + amiloride on blood pressure in men with mild to moderate hypertension.
    Otterstad JE; Froeland G; Erikssen J
    Scand J Clin Lab Invest; 1993 Apr; 53(2):155-62. PubMed ID: 8469914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Lakshman MR; Reda DJ; Materson BJ; Cushman WC; Freis ED
    Arch Intern Med; 1999 Mar; 159(6):551-8. PubMed ID: 10090111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension.
    Mattioli AV; Bonatti S; Monopoli D; Zennaro M; Mattioli G
    Blood Press; 2005; 14(5):273-8. PubMed ID: 16257872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Materson BJ; Reda DJ; Preston RA; Cushman WC; Massie BM; Freis ED; Kochar MS; Hamburger RJ; Fye C; Lakshman R
    Arch Intern Med; 1995 Sep; 155(16):1757-62. PubMed ID: 7654109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regression of left heart hypertrophy in arterial hypertension: principles, experimental and clinical findings].
    Klaus D
    Z Kardiol; 1985; 74 Suppl 7():153-69. PubMed ID: 2936016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA).
    Agabiti-Rosei E; Trimarco B; Muiesan ML; Reid J; Salvetti A; Tang R; Hennig M; Baurecht H; Parati G; Mancia G; Zanchetti A;
    J Hypertens; 2005 May; 23(5):1091-8. PubMed ID: 15834297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial.
    Devereux RB; Palmieri V; Sharpe N; De Quattro V; Bella JN; de Simone G; Walker JF; Hahn RT; Dahlöf B
    Circulation; 2001 Sep; 104(11):1248-54. PubMed ID: 11551875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left atrial size in hypertensive men: influence of obesity, race and age. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Gottdiener JS; Reda DJ; Williams DW; Materson BJ
    J Am Coll Cardiol; 1997 Mar; 29(3):651-8. PubMed ID: 9060907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
    Malmqvist K; Kahan T; Edner M; Bergfeldt L
    Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.